In vitro Antiplatelet Aggregation Activity of Centella asiatica (L.) Urban Ethanolic Extract by Lestari, Agatha Budi Susiana
Available online at www.ijpcr.com 
International Journal of Pharmaceutical and Clinical Research 2016; 8(4): 280-283 
     
                                                                                                                       ISSN- 0975 1556 
Research Article 
*Author for Correspondence 
In Vitro Antiplatelet Aggregation Activity of Centella asiatica (L.) 
Urban Ethanolic Extract 
 
Agatha Budi Susiana Lestari1,2, Achmad Fudholi3*, Akhmad Kharis Nugroho3, Erna Prawita 
Setyowati4 
 
1Postgraduate program of Pharmaceutical Sciences, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, 
Indonesia 
2Department of Pharmaceutical Technology, Faculty of Pharmacy, Sanata Dharma University, Yogyakarta, Indonesia 
3Department of Pharmaceutics, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia 
4Department of Pharmaceutical Biology, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia 
 
Available Online:01st April, 2016 
 
ABSTRACT 
The death on cardiovascular disease can be caused by thrombosis. Thrombosis is triggered by irreversible activity of 
thrombocyte aggregation. However, almost all prescribed drugs exhibiting antiplatelet activity are associated with a large 
number of side effects. Then, exploration of medicinal plants which have cardioprotective activity especially as antiplatelet 
aggregation agent are needed. One of the medicinal plant, Centella asiatica (L.) Urban, has been known to keep people’s 
health. This study was undertaken to investigate anti-platelet aggregation activity of Centella asiatica ethanolic extract 
(CEE). There were two groups of CEE, the first group was n-hexane purified CEE (pCEE) while the second group was 
non-purified CEE (npCEE). In vitro study of antiplatelet aggregation was evaluated by Born method using a Model 490 
Chrono Log aggregometer. The blood plasma of male Sprague dawley rats were collected and 10 μM adenosine diphosphat 
(ADP) was used as agonist. The results showed that both of pCEE and npCEE had anti-platelet aggregation activity on the 
range concentration of 200, 400, and 800 µg/ml. However, antiplatelet aggregation activity of pCEE and npCEE were not 
different statistically. Purification process using n-hexane on Centella asiatica herbs powder does not influence its 
antiplatelet aggregation activity. 
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INTRODUCTION 
Platelet aggregation has many benefits for organism such 
as on homeostasis, xenobiotic phagocytoses, interaction 
with virus, bacteria or antigen-antibody complexes. 
However, it also has dangerous effects. Hyperactivity of 
thrombocyte function leads to the increase of thrombocyte 
aggregation which can cause arterial thrombosis and 
embolism. Thrombosis and embolism can increase the risk 
factor of cardiovascular disease1. Thrombocyte 
aggregation assay was done to detect the thrombocyte 
abnormality function and it can be analysed by 
macroscopic, microscopic, or using other agonist like 
ADP, collagen, epinephrine, or ristosetin. Commonly used 
of antiplatelet agents such as clopidogrel and aspirin are 
widely used clinically2, but they have various side effects. 
For this reason, studies have been conducted to search for 
naturally derived antiplatelet aggregation with fewer side 
effects.   
From in vitro study, Centella asiatica (CA) has been 
known to have some pharmacodynamic activities such as 
wounds healing3, anti peptic ulcer4, mental disorders, 
antiviral, fungicidal, antibacterial and many others5.  CA 
herbs are usually used for some therapy like 
gastrointestinal disease, dermatitis, infection disease, etc5. 
The main compound of CA and also as a marker 
constituent on quality control is asiaticoside, a triterpene 
compound6.  CA has been shown to decrease the 
malonaldehyde (MDA) level, in addition, catalase activity 
was found to be significantly higher7. These effects may be 
attributed to the antioxidant compound present in CA, and 
in particular the flavonoids, quercetin, cathecin and rutin, 
that are known to be potent antioxidant7. The antioxidant 
activity of CA could be developed as the prevention agent 
for degeneration diseases such as antiplatelet aggregation 
which could lead to stroke or heart disease. 
Extraction was used to obtain higher number of active 
compounds from CA herbs. To obtain high quality extract, 
it could be done by purification or without purification. In 
previous study, n-hexane purification process affects some 
quality parameters of CEE such as the number of 
asiaticoside content, IC50, and total phenolic content8. 
The aim of this research is to determine the influence of n-
hexane purification process on CA herbs powder towards 
its ethanolic extract anti-platelet aggregation activity. 
Platelet aggregation tests were done by Born method using 
a 490 model Chrono-Log. 
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MATERIALS AND METHODS 
Materials 
CA herbs were obtained from Balai Besar Penelitian dan 
Pengembangan Tanaman Obat dan Obat Tradisional  
(B2P2TOOT/Research and Development Centre of 
Medical Plants and Traditional Medicine) Tawangmangu, 
Central Java, Indonesia, acetosal (PT Konimex), ginkgo  
biloba dried extract (Javaplant). 
Reagents 
Ethanol (Brataco), n-hexane (Brataco), DMSO (p.a., 
Merck), ADP (Chrono-Par. cat 384), saline (NaCl 0.9%, 
308 mOsm/L, Otsuka).  
Animals 
Two months old male Sprague dawley rats (180-200 
grams) were purchased from Imono Laboratory, Faculty of 
Pharmacy, Sanata Dharma University, Yogyakarta. Each 
4-5 rats were placed on the box at 24-25oC in a room with 
an automatically controlled 12hours light-dark cycle. 
Upon arrival, rats were fed by BR2 once a day and 
acclimated to the facility for 7 days before the experiment. 
Rats had free access to de-ionized water and the assigned 
diet for along the study. Ethical clearance was acquired 
from ethical commission for animal study of Laboratorium 
Penelitian dan Pengujian Terpadu (LPPT/Integrated 
Research and Testing Laboratory) Gadjah Mada 
University. 
Extraction of Centella asiatica herbs 
Dried herbs were sorted and grinded into powder with the 
size of 12/40. There were two kinds of powders which 
would be extracted, n-hexane purified CA herbs powders 
(group I) and non-purified CA herbs powders (group II). 
In group I, CA powder which had been purified using n-
hexane was evaporated until all solvent gone away. After 
that, both of them  (group I and II) were extracted by 
maceration using ethanol and water (3:1). Each dried 
powder and solvent (1:10) were mixed in erlenmeyer and 
macerator was turned on at 177 rpm for 24 hours. The 
supernatant was separated and re-maceration was started 
again. All of the supernatant were collected and the solvent 
was evaporated to obtain viscous Centella asiatica 
ethanolic extract (CEE). 
Test sample preparation 
To obtain 2 mg/ml stock solution, CEE was dissolved in 
50 ml DMSO. After that, further dilutions from stock 
solution were done to make range concentration of 100, 
200, 400, 800, and 1600 μg/ml. Ginkgo biloba extract was 
used as a reference with the range concentration of 50, 100, 
200, 400, and 800 μl/ml and 1 mM acetosal.  





1 2 3 4 5 (mean±SEM
) 
100 29 19 18 17 20 20.6 ± 2.15 
200 9 18 25 13 9 14.8 ± 3.03 
400 17 12 35 14 10 17.6 ± 4.50 
800 19 23 23 16 17 19.6 ± 1.46 
1600 19 16 29 15 27 21.2 ± 2.87 
level of significance p<0.05. 
 





1 2 3 4 5 (mean±SEM) 
100 20 34 24 18 28 24.8 ± 2.87 
200 17 16 13 24 10 16.0 ± 2.34 
400 19 28 19 16 12 18.8 ± 2.63 
800 35 14 18 12 18 19.4 ± 4.06 
1600 28 27 14 20 14 20.4 ± 2.92 
level of significance p<0.05 
 
Table 3: The effect of DMSO on % platelet 
aggregation 
% aggregation 
1 2 3 4 5 (mean±SEM) 
24 25 25 39 28 28.2 ± 2.78 
      
 
Figure 1. Baseline curve of 10µM ADP 
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Figure 2: Curve of CEE (pCEE and npCEE)  activity on 
platelet aggregation (%). 
 
Preparation of platelet-rich plasma (PRP) and platelet-
poor plasma (PPP) 
Rats (Sprague dawley) arterial blood were collected and 
anti-coagulated with 0.11 M trisodium citrate (3% citrate-
whole blood, 1:9, v/v)9. The citrated whole blood was 
centrifuged at 1000 rpm for 15 minutes and the PRP 
aspirated. PPP was obtained by further centrifugation 
(3500 rpm, 15 minutes) of the residual blood. After that, 
PPP was moved to other tube. 
ADP Preparation 
ADP was dissolved in a bottle which contained 5 ml saline 
solution. Each 40 μl of ADP solution was moved to 
microtube and stored in -70oC (stable for one year). The 
ADP solution was melted on temperature room and it will 
stable for 8 hours in 2-8oC. 
Platelet Aggregation 
CEE (pCEE and npCEE) ability on anti-platelet 
aggregation was determined using Born method with some 
modifications. This method based on turbidimetric 
principal using a Model 490 Chronolog aggregometer. In 
aggregometer cuvette, PRP and PPP were added for about 
500 μl each cuvette. After that, all of them were incubated 
for 5 minutes in incubation wells. For about 5 μl of test 
compound (CEE) was added to pre-treated PRP aliquots 
and after one min aggregation was initiated by addition of 
10 μM ADP and the responses were recorded for ten 
minutes. A magnetic bar was added in each cuvette and 
then the cuvette were inserted in optical chamber. The 
chambers were stirred for 3 minutes. For about 5 μl CEE  
was added in PRP cuvette and stirred for 1 minute. For 
about 5 μl of 10 μM ADP agonist was added in PRP  
cuvette and let the reaction flow for 10 minutes. 
 
RESULTS AND DISCUSSION 
Platelet aggregation was performed using the turbidimetric 
method based on the change of light transmissions. When 
the light is passed by plasma which contained PRP, a little 
light transmission will be resulted. Thrombocyte 
aggregation will appear after agonist addition. Therefore, 
the plasma becomes clear and it causes bigger light 
transmission. Platelet aggregation activity was determined 
by the difference of light transmission10. 
ADP concentration as the agonist should be looked 
carefully. Lower concentration of ADP can cause 
thrombocyte aggregation which is followed by 
deaggregation. Meanwhile, higher concentration of ADP 
causes monophasic curve which cannot differentiate the 
 
Table 4: The effect of positive control on % platelet aggregation 
No Treatment Concentration % aggregation  
1 2 3 4 5 (mean±SEM) 
1  Ginkgo Biloba Extract 
(GBE) 
50 µg/ml 16 13 15 12 28 16.8 ± 2.88 
100 µg/ml 22 15 16 20 5 15.6 ± 2.94 
200 µg/ml 15 8 13 20 18 14.8 ± 2.08 
400 µg/ml 19 17 11 15 7 13.8 ± 2.15 
800 µg/ml 20 13 7 16 9 13.0 ± 2.34 
2 Acetosal  1 mM 11 12 18 21 18 16.0 ± 1.92 
level of significance p<0.05 
 
 
Figure 3: Comparative effect of pCEE, npCEE, GBE, Acetosal, and DMSO on platelet aggregation (%) 
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normal thrombocyte and the hyperactive thrombocyte10. In 
this study, 10µM ADP was used, and the baseline curve 
was shown at figure 1. ADP as agonist performed high 
platelet aggregation activity, which is 34.2 ± 2.81 % (taken 
from 5 replications, mean±SEM). When CEE was added 
on PRP, after 10 minutes, the percentage of platelet 
aggregation has smaller than ADP baseline. It means that 
CEE can decreased the platelet aggregation activity. Figure 
2 showed that the ability of pCEE and npCEE to induce 
platelet aggregation were dose independent manner. Both 
of them also had similar profile, having the lowest % 
platelet aggregation on the concentration of 200 µg/ml. 
When the bigger concentrations (>200 µg/ml) were given, 
the percentage of platelet aggregation tended to increase 
although still lower than the smallest concentration (100 
µg/ml). Both of pCEE and npCEE at concentration 200, 
400, and 800 µg/ml performed antiplatelet aggregation 
activity significantly compared to negative control DMSO. 
The lower number of % platelet aggregation indicated 
stronger antiplatelet aggregation activity. At the 
concentration of 200 µg/ml, % platelet aggregation of 
pCEE (15.4 ± 3.24) and npCEE (16.0 ± 2.34) were not 
different statistically. It showed that n-hexane purification 
process on CA herbs powder did not affect the antiplatelet 
aggregation activity. In this study, two kinds of positive 
control were used, ginkgo biloba extract (GBE) and 
acetosal. GBE was used as medicinal plant representative 
which had been proven to has antioxidant and antiplatelet 
activities at the concentration of 80 µg/ml11. We used 
serial concentration of GBE: 50, 100, 200, 400, and 800 
µg/ml. At the concentration used, GBE also performed 
platelet aggregation activity significantly compared to 
negative control DMSO. Acetosal was used as chemical 
drugs representative which had been known to has 
antiplatelet aggregation activity. Based on the Table 3, 1 
mM acetosal induced platelet aggregation as much as 
npCEE (200 µg/ml), for about 16.0%. The comparative 
effect of Comparative effect of pCEE, npCEE, GBE at 
same concentration, acetosal, and DMSO on platelet 
aggregation (%) was shown in figure 3. 
 
CONCLUSIONS 
In vitro study showed that Centella asiatica herbs 
ethanolic extract (CEE) had antiplatelet aggregation 
activity. In this study, antiplatelet aggregation activity of 
CEE was performed at the concentration of 200, 400, and 
800 µg/ml. n-hexane purification on the Centella asiatica 
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